An international team of researchers, led by the University of Edinburgh and King’s College in London, analyzed data from over five million people from 29 countries. For the first time, such broad demographic coverage has enabled the discovery of 70 genetic variations associated with depression, half of which have not been previously studied. The study, published in the journal Cell, covered 29 countries and included participants from different ethnic groups.
This has enabled the identification of genetic variations that have not previously been associated with depression and a better understanding of how they affect the development of this condition. About 280 million people worldwide suffer from depression, and in addition to life difficulties and stress, this condition also has a genetic component. The studied changes in DNA are associated with neurons in different parts of the brain, including those that control emotions.
Scientists believe that these discoveries will enable more accurate prediction of the risk of depression, regardless of the patient’s ethnic origin, and the development of more diverse treatment options. More than 1.60 drugs were specifically studied to assess their impact on genes associated with depression. In addition to known antidepressants, new potential drugs have been identified. For example, Pregabalin and Modafinil, which were originally used to treat chronic pain and narcolepsy, have shown an effect on the same genes as antidepressants.
For a final assessment of their effectiveness in depression, additional clinical trials will be needed. Researchers hope that these results will contribute to reducing inequalities in access to health care and improving the quality of life of millions of people around the world.
